Inhaled gene therapy company launches to treat rare respiratory disorders

AlveoGene, a UK-based company focused on transforming rare respiratory disease outcomes using inhaled gene therapy has announced its launch.

The company has been set up in conjunction with seed funding raised from Oxford Science Enterprises (OSE), Harrington Discovery Institute at University Hospitals (Harrington), and with participation from Old College Capital (OCC), the University of Edinburgh’s venture investment fund.

AlveoGene has been created by OSE, Harrington and OCC in partnership with six leading scientists from the UK Respiratory Gene Therapy Consortium (GTC).